Project Grant R21AI193882
- The U.S. Department of Health and Human Services National Institutes of Health (NIH) awarded a $156,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Medical College of Wisconsin, Inc. The overall objective of this 2-year project, from August 1, 2025 to July 31, 2027, is to develop a panel of biomarkers that can discriminate between exposure of upper- and lower-body organs to radiation and predict health outcomes. The research aims to identify organ-specific...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $155,857 Project Grant under the Trans-NIH Research Support (CFDA 93.310) program to Signablok, Inc. in Massachusetts. The funding supports the development of a novel medical countermeasure to mitigate potentially lethal acute radiation syndrome (ARS). The project aims to create a well-tolerable and effective first-in-class therapeutic that can be administered at least 24 hours post-radiation exposure...
- The U.S. Department of Health and Human Services' National Institutes of Health (NIH) awarded a $170,800 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to New York Blood Center, Inc. The goal of the research project is to understand the mechanism underlying sex-specific effects in the regulation of radiation response and to develop a novel radiation countermeasure that targets such differences. The project aims to determine the cellular and molecular mechanisms of LXN...
- Albany Medical College received a $733,500 Project Grant award from the Defense Health Agency dated June 1, 2023 through May 31, 2026 under the Military Medical Research and Development federal grant program (CFDA 12.420). Through this award, Albany Medical College will conduct research investigating medical solutions for the battlefield by harnessing RVE1 to treat bone marrow failure. The Military Medical Research and Development program aims to transform military and public health through...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) totaling $157,000.00 is supporting research to develop a new class of radiation mitigating agents as medical countermeasures for hematopoietic acute radiation syndrome (H-ARS). The principal investigators from the collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences will examine the mitigating effects of the small molecule...
- This $164,500 Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports the development and validation of human normal tissue patient-derived organoids (NT-PDOs) for pre-screening new candidate gastrointestinal (GI) radiation countermeasure drugs. The goal is to create an extracorporeal model based on healthy human GI tissue that can accurately assess the efficacy and safety of radiation mitigators, addressing limitations of...
- This Project Grant award of $153,000.00, provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), focuses on investigating potential radiomitigating strategies for gastrointestinal acute radiation syndrome (GI-ARS). The research project has two novel approaches: 1) Evaluating the mitigating effects of dietary methionine restriction on GI-ARS following radiation exposure, and 2) Exploring a second approach outlined in Aim 2 (details not...
- This federal Project Grant award from the Defense Health Agency supports Albany Medical College's research project titled "TARGETING DENDRITIC CELLS TO PREVENT HBV CHRONIC DISEASE". The $2,464,874 award, which runs from July 1, 2024 to June 30, 2028, is funded through the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420). The project aims to advance medical knowledge and improve healthcare for military service members, veterans, and their...
- The National Institutes of Health (NIH) awarded a $156,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Georgetown University on August 11, 2025. The project, titled "Development of a Multiomic Biodosimetry Panel for Use During Sepsis and Antibiotic Treatment", aims to develop a novel panel of metabolomic and gene expression biomarkers to rapidly screen and provide accurate dose reconstruction for individuals exposed to ionizing radiation. This panel will...
- This federal Cooperative Agreement award of $583,468 was issued on September 16, 2025 by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The award is funding research to develop a small-molecule drug, referred to as MH01, that can stabilize the BRCA2-RAD51 complex to enhance DNA double-strand break repair and mitigate tissue damage caused by ionizing radiation exposure. The research aims to optimize the MH01 regimen, assess its...
The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $164,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to Albany Medical College. The grant supports research into "Specialized Pro-Resolving Lipid Mediators for Systemic Radiation Countermeasures". The research aims to develop new therapies to address radiation-induced damage, including hematopoietic effects and chronic inflammation, which can result from occupational exposure, accidents, or acts of terrorism/warfare. The project period runs from August 5, 2025 through July 31, 2027. Albany Medical College, a private non-profit academic medical institution, will lead this research, which may involve collaborations with other universities and research organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $164.0k | 8/5/25 |